Bioprinting

  • Photo of nScrypt and taking bioprinting to the field

    The medical AM segment is multifaceted, consisting of 3D printed medical devices, anatomical models, prosthetics and more. Within the industry, bioprinting has carved out a prominent position, gaining interest across the board for its huge potentials in drug development and screening, therapeutic treatments and regenerative medicine, to name but a few. While much of…

    Read More
  • Photo of Aspect Biosystems and the restorative capacity of bioprinting today

    The medical AM segment is multifaceted, consisting of 3D printed medical devices, anatomical models, prosthetics and more. Within the industry, bioprinting has carved out a prominent position, gaining interest across the board for its huge potentials in drug development and screening, therapeutic treatments and regenerative medicine, to name but a few. While…

    Read More
  • Photo of Biogelx and the role of bioinks in bioprinting today

    The medical AM segment is multifaceted, consisting of 3D printed medical devices, anatomical models, prosthetics and more. Within the industry, bioprinting has carved out a prominent position, gaining interest across the board for its huge potentials in drug development and screening, therapeutic treatments and regenerative medicine, to name but a…

    Read More
  • Photo of RegenHU and the role of iPSCs in bioprinting today

    The medical AM segment is multifaceted, consisting of 3D printed medical devices, anatomical models, prosthetics and more. Within the industry, bioprinting has carved out a prominent position, gaining interest across the board for its huge potentials in drug development and screening, therapeutic treatments and regenerative medicine, to name but a…

    Read More
  • Photo of CELLINK and the accessibility of bioprinting today

    The medical AM segment is multifaceted, consisting of 3D printed medical devices, anatomical models, prosthetics and more. Within the industry, bioprinting has carved out a prominent position, gaining interest across the board for its huge potentials in drug development and screening, therapeutic treatments and regenerative medicine, to name but a…

    Read More
  • Photo of T&R Biofab and Ethicon bioprinting soft tissue scaffolds for wound treatment

    Bioprinting company T&R Biofab has announced a new collaboration agreement with Ethicon, Inc., a Johnson & Johnson Medical Device Company. The aim of the partnership is to develop a 3D bioprinted soft tissue scaffold for wound treatments, reconstructive surgery and more. Based in South Korea, T&R Biofab develops and commercializes…

    Read More
  • Photo of Poietis and Marseille-based hospital partner for bioprinted skin clinical trial

    French bioprinting company Poietis has entered into a clinical research collaboration with the Assistance Publique – Hôpitaux de Marseille (AP-HM) to pursue a clinical trial for bioprinted skin tissue. Through the partnership, Poietis and AP-HM aim to carry out a Phase I clinical trial for an Innovative Advanced Therapeutic Medicinal Product…

    Read More
  • Photo of 3D printed ceramic fluid manifolds improve in-space bioprinting

    Over 400 kilometers from Earth, advances are being achieved in the field of bioprinting. In November, the 3D BioFabrication Facility (BFF) was delivered to the International Space Station, where it is being used to test how bioinks and printed human cells react in a microgravity environment. As it turns out,…

    Read More
  • Photo of El Paso researchers sending bioprinted mini hearts to ISS

    Biomedical researchers from Texas Tech University Health Sciences Center El Paso and the University of Texas at El Paso are working on a joint project to send miniature 3D bioprinted hearts to space. The research project, which has received backing from the National Science Foundation (NSF), seeks to understand how…

    Read More
  • Photo of Organovo merges with Tarveda Therapeutics, ceases bioprinting operations

    Organovo and Tarveda Therapeutics, a privately-held, clinical-stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines (Pentarin miniature drug conjugates) have entered into a definitive merger agreement. Under the terms of the deal, Tarveda merges with a wholly-owned subsidiary of Organovo in an all-stock transaction. Upon completion of the…

    Read More
Back to top button

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Close
Close

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!